Crescent Biopharma announced its second quarter 2026 financial results, highlighting progress in multiple clinical trials for cancer therapies, including CR-001, a PD-1 x VEGF bispecific antibody, and antibody-drug conjugates CR-002 and CR-003. The company is enrolling patients globally in Phase 1/2 trials and expects key clinical data readouts starting Q1 2027. Crescent completed a $143.7 million public offering in July 2026, extending its cash runway into the second half of 2028, supporting ongoing development and upcoming clinical milestones.
Krystal Biotech reported a strong Q2 2026 with earnings per share of $1.79, beating analyst estimates and up from $1.29 last year. Revenue grew 24% year-over-year to $119.22 million, mainly due to global sales of its gene therapy VYJUVEK for dystroph...
Diamondback Energy is expected to report a 127.7% jump in Q3 2026 earnings per share to $6.08 and a 31.1% rise in revenue to $4.82 billion, driven by robust oil production and efficiency improvements from advanced drilling technologies. Despite a rec...
MannyPay Global Inc., chaired by Manny Pacquiao, has launched a global payment facilitator platform in partnership with iMerchant and powered by Adyen. The platform supports merchants across more than 70 countries and 135 currencies with features lik...
KKR has agreed to acquire Integer Holdings Corporation, a medical-device outsourcing company, for approximately $5.7 billion at $127 per share. This offer represents a 51.8% premium over Integer's closing price on April 29, 2026, and a 28.8% premium ...
Bowhead Specialty Holdings Inc. is being acquired by American Family Mutual Insurance for $1.2 billion in an all-cash deal. Following the announcement, Piper Sandler downgraded Bowhead's stock rating to Neutral due to limited short-term growth potent...
